Drug intelligence / Profile preview

alprazolam + sulpiride

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

**Alprazolam + sulpiride** is a combination of two pharmaceutical agents: alprazolam, a benzodiazepine anxiolytic, and sulpiride, a substituted benzamide antipsychotic. Alprazolam acts as a central nervous system depressant by enhancing the inhibitory activity of the GABA(A) receptor, resulting in anxiolytic, sedative, and muscle relaxant effects. Sulpiride acts primarily as a selective antagonist of the dopamine D2 (and to a lesser extent, D3) receptors, exerting antipsychotic action, particularly in schizophrenia and other psychotic disorders. The combination is used off-label in some psychiatric settings to manage symptoms involving severe anxiety with psychosis or depression, but there is no evidence of a fixed-dose combination product being widely approved for this indication. Caution is warranted when using these drugs together due to an increased risk of central nervous system depression, requiring close monitoring and dose adjustment by a healthcare provider[1][2][4][5].

02

Targets

DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)DRD2 (Dopamine D2 Receptor)SLC47A1 (Multidrug and toxin extrusion transporter 1)CA2 (Carbonic Anhydrase 2)OCT3 (Organic cation transporter 3)BZD site (GABA-A receptor benzodiazepine site)

Beyond the preview

Go deeper on alprazolam + sulpiride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alprazolam + sulpiride.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call